Condition

Obese Non Diabetic

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 2 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting0

Common interventions7

Lead sponsors shown2

Clinical trials

2 shown

Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical TrialNCT07820111 · 2025-10-18

COMPLETED

The Effects of Sodium Phenylbutyrate on Circulating Branched Chain Amino AcidsNCT05028803 · 2021-09-01

COMPLETED

Common interventions

Dulaglutide 0.75mg subcutaneous injectionDRUG1 Dulaglutide 1.5 MG/MLDRUG1 Semaglutide 1.0 mgDRUG1 Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solutionDRUG1 sodium phenylbutyrateDRUG1 Tirzepatide (Flexible titration)DRUG1 Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physicianDRUG1

Leading sponsors

University of Nottingham 1 Zagazig University 1

Trial status mix

COMPLETED2

Phase mix

NA1

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.